The federal hantavirus response has laid bare the impact of the Trump administration’s cuts to U.S. and global health, renewing concerns among public health experts that the U.S. is not prepared for a bigger health crisis. Career scientists at the Centers for Disease Control and Prevention (CDC) have been fired or left the agency, and there are far fewer people available to respond…
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
